Forest Holidays (or the “Company”), which owns and operates secluded eco-cabins and treehouses on nine sites across Britain’s National Forests, is pleased to announce that Phoenix Equity Partners (or “Phoenix”), the mid-market private equity firm, is acquiring a controlling stake alongside existing shareholders The Forestry Commission and LDC.Read More
Phoenix Equity Partners, a leading UK middle-market private equity firm, is pleased to announce that it has entered into a binding contract to sell Riviera Travel to Silverfleet Capital.Read More
Phoenix Equity Partners (“Phoenix”) announces today the sale of Porthaven Group Holdings (“Porthaven”), owner and operator of premium quality care homes, to Fremont Realty Capital (“Fremont”) and co-investors. Financial details of the transaction are not disclosed.Read More
GNS launches VOYAGER Hub: a new generation back of bridge software solution for commercial shipping. The release of VOYAGER Hub enables GNS to meet growing demand for improved user experience and ship and shore cost savings and efficiencies.Read More
Phoenix Equity Partners ("Phoenix"), a leading UK middle-market private equity firm, today announces an investment in Sygnature Discovery Limited (“Sygnature” or “the Company”) alongside the current management team, led by CEO and founder Simon Hirst. The transaction will provide Sygnature with additional investment to support the Company’s continued development and growth.
Sygnature is a leading provider of outsourced drug discovery services to UK and overseas biotech and pharma companies. Sygnature operates from state of the art facilities in Nottingham and employs over 200 staff, most of whom are PhD scientists. Phoenix will work with Simon Hirst and the Sygnature management team to accelerate the growth of the business.
Kevin Keck, Partner at Phoenix, said: “Sygnature is a very well-respected business with a strong reputation in an attractive and growing segment of the pharma services sector. Simon and his team have built a great company with a fantastic track record of undertaking high quality scientific research. We are delighted to be partnering with them at a time of continuing rapid growth and significant opportunity in the drug discovery market.”
Simon Hirst, CEO of Sygnature, commented: “We are extremely proud of our people and our culture at Sygnature, which is focused on undertaking leading edge research in drug discovery and providing a great service for our customers. We are excited to be working with Phoenix – our partnership will provide us with investment to expand our business further and to provide a broader range of services for our customers.”
Sygnature is Phoenix’s fourth investment from its 2016 Fund and third this year, following investments in The Travel Chapter, Rayner Surgical and Global Freight Solutions
Bridge Leisure Parks has continued its rapid growth on the back of the UK’s buoyant staycation market by acquiring three new holiday parks for a total investment of £11million.Read More
Phoenix Equity Partners (“Phoenix”), a leading UK middle-market private equity firm, is pleased to announce that it has completed the sale of Key Retirement Group (“KRG” or “the Company”), a leading provider of financial products for retirees, to funds managed and/or advised by Partners Group, a global private markets investment manager, for a transaction value of £208 million. The transaction was first announced on 18 April 2017 and has now received regulatory approval.Read More
Phoenix Equity Partners has completed the raising of its fourth fund, Phoenix Equity Partners 2016 (the “Fund” or the “2016 Fund”), with commitments of £415 million.Read More